Madison-based Mirus Bio, a manufacturer of transfection regents used in gene therapies, has entered into an agreement to be acquired by MilliporeSigma for $600 million.
MilliporeSigma is the life sciences business of German company Merck KGaA, which is not affiliated with pharmaceutical giant Merck & Co.
“We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, chief executive officer of Mirus Bio. “MilliporeSigma’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”
;
